A carregar...
Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice
BACKGROUND: Regorafenib is an orally administered multikinase inhibitor that has been approved for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). Even though regorafenib significantly improved survival in two international phase 3 trials (CORRECT and CONCUR), a high rate...
Na minha lista:
| Publicado no: | Clin Med Insights Oncol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Libertas Academica
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4933532/ https://ncbi.nlm.nih.gov/pubmed/27398042 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMO.S38335 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|